Abstract CT167: Trial in Progress: Phase 1 Dose Escalation Study of T-1101, a First-in-class Oral Hec1/Nek2 Inhibitor, in Patients with Advanced Refractory Solid Tumors
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined